Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allylestrenol vs progesterone for threatened abortion with subchorionic hematoma
ChiCTR2500107901Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of allylestrenol in threatened abortion and Subchorionic hematoma (SCH) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Difference in SCH/gestational sac ratio at 4 weeks vs baseline and Neonatal outcomes. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
allylestrenol
03
Conditions
threatened abortionSubchorionic hematoma (SCH)
Beyond the preview
Go deeper on ChiCTR2500107901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107901.